Experimental Phage Therapy against Staphylococcus aureus in Mice | Zendy

Rosanna Capparelli | Zendy; Marianna Parlato | Zendy; Giorgia Borriello | Zendy; Paola Salvatore | Zendy; Domenico Iannelli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Experimental Phage Therapy against Staphylococcus aureus in Mice

Author(s) -

Rosanna Capparelli,

Marianna Parlato,

Giorgia Borriello,

Paola Salvatore,

Domenico Iannelli

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01513-06

Subject(s) - staphylococcus aureus , microbiology and biotechnology , bacteriophage , phage therapy , clearance , in vivo , staphylococcal infections , virology , bacteria , biology , staphylococcus , micrococcaceae , antibiotics , antibacterial agent , medicine , escherichia coli , biochemistry , genetics , urology , gene

The present study describes a bacteriophage (M(Sa)) active against Staphylococcus aureus, including methicillin-resistant staphylococcal strains. When inoculated into mice simultaneously with S. aureus A170 (10(8) CFU/mouse), phage (10(9) PFU) rescued 97% of the mice; when applied to nonlethal (5 x 10(6) CFU/mouse) 10-day infections, the phage also fully cleared the bacteria. The phage M(Sa), delivered inside macrophages by S. aureus, kills the intracellular staphylococci in vivo and in vitro. The phage can also prevent abscess formation and reduce the bacterial load and weight of abscesses. These results suggest a potential use of the phage for the control of both local and systemic human S. aureus infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research